While ACT-DC treatment in Batf3−/− mice significantly delayed tumor growth (Supplementary Fig. 39b) and improved survival rates (Fig. 6t), its therapeutic efficacy was markedly reduced compared to that in the wild-type mice. This evidence concerns the gene BATF3 and neoplasm.